Market Place
Sourcing Support
Acadia nabs rights to Saniona`s tremor asset in $582M biobucks deal
27 Nov 2024 //
FIERCE BIOTECH
Acadia Pharma Announces License Agreement with Saniona for SAN711
26 Nov 2024 //
BUSINESSWIRE
Saniona AB’s Nomination Committee for the Annual General Meeting 2023
25 Nov 2022 //
GLOBENEWSWIRE
Saniona’s anti-inflammatory candidate SAN903 is ready for clinical studies
02 Nov 2022 //
GLOBENEWSWIRE
Saniona extends runway and amends loan agreement with Formue Nord
30 Sep 2022 //
GLOBENEWSWIRE
Saniona publishes its interim report for the second quarter of 2022
25 Aug 2022 //
GLOBENEWSWIRE
Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022
18 Aug 2022 //
GLOBENEWSWIRE
Saniona provides update on outstanding option programs
05 Aug 2022 //
GLOBENEWSWIRE
Notice of extraordinary general meeting in Saniona AB
15 Jul 2022 //
GLOBENEWSWIRE
Saniona CEO T. Feldthus & board member C. Johan Sundberg purchase Saniona shares
06 Jul 2022 //
GLOBENEWSWIRE
Saniona reports positive top line results from the SAN711 Phase 1 Clinical Trial
30 Jun 2022 //
GLOBENEWSWIRE
Saniona`s preclinical candidate SAN903 shows robust dampening of fibrosis in CKD
24 Jun 2022 //
GLOBENEWSWIRE
Bulletin from the Saniona AB annual shareholders` meeting on May 25, 2022
25 May 2022 //
GLOBENEWSWIRE
Saniona publishes its interim report for the first quarter of 2022
25 May 2022 //
GLOBENEWSWIRE
Saniona`s Clinical Trial in Hypothalamic Obesity Published in Scientific Journal
23 May 2022 //
GLOBENEWSWIRE
Saniona provides update on ongoing review of tesofensine in Mexico
20 May 2022 //
GLOBENEWSWIRE
Saniona publishes its Annual Report for 2021
30 Apr 2022 //
GLOBENEWSWIRE
Saniona Changes Date of Annual Report for 2021
27 Apr 2022 //
GLOBENEWSWIRE
Saniona Announces Refocused Strategy on Ion Channel R&D and Restructuring
25 Apr 2022 //
GLOBENEWSWIRE
Saniona Announces Strategic Program Prioritization and Restructuring
29 Mar 2022 //
GLOBENEWSWIRE
Saniona Initiates PET Stage of SAN711 Phase 1 Clinical Trial
24 Mar 2022 //
GLOBENEWSWIRE
Saniona ion channel research collaboration with BI advances to next stage
21 Mar 2022 //
GLOBENEWSWIRE
Saniona to participate in multiple upcoming investor conferences
01 Mar 2022 //
GLOBENEWSWIRE
Saniona publishes its year-end report for 2021
24 Feb 2022 //
GLOBENEWSWIRE
Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial
10 Feb 2022 //
GLOBENEWSWIRE
Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome
28 Dec 2021 //
GLOBENEWSWIRE
Saniona AB’s Nomination Committee for the Annual General Meeting 2022
25 Nov 2021 //
GLOBENEWSWIRE
Saniona Initiates Phase 2b Clinical Trial of Tesomet for Hypothalamic Obesity
17 Nov 2021 //
GLOBENEWSWIRE
Saniona completes submission of manufacturing data for Tesomet
18 Oct 2021 //
GLOBENEWSWIRE
Saniona Submits CMC Program for Tesomet Capsules
18 Oct 2021 //
CONTRACTPHARMA
Saniona to participate in multiple upcoming virtual investor conferences
06 Oct 2021 //
GLOBENEWSWIRE
Saniona appoints Robert Hoffman to Board of Directors
16 Sep 2021 //
GLOBENEWSWIRE
Saniona appoints Wendy Dwyer as Chief Business Officer
15 Sep 2021 //
GLOBENEWSWIRE
Saniona publishes its interim report for the second quarter of 2021
26 Aug 2021 //
GLOBENEWSWIRE
Saniona U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity
26 Jul 2021 //
GLOBENEWSWIRE
Saniona secures SEK 87 million ($10 million) non-dilutive term loan
14 Jul 2021 //
GLOBENEWSWIRE
Saniona Initiates Phase 1 Clinical Trial of SAN711
30 Jun 2021 //
GLOBENEWSWIRE
Bulletin from the Saniona extraordinary shareholders’ meeting on June 29, 2021
29 Jun 2021 //
GLOBENEWSWIRE
Saniona provides update on ongoing review of tesofensine in Mexico
25 Jun 2021 //
GLOBENEWSWIRE
Saniona to Present Preclinical Data on SAN711
08 Jun 2021 //
GLOBENEWSWIRE
Saniona to Host R&D Day on Ion Channel Targeting Expertise for Rare Diseases
12 May 2021 //
GLOBENEWSWIRE
Saniona Updates Tesomet Clinical Development Timelines Based on Manufacturing
22 Apr 2021 //
GLOBENEWSWIRE
Saniona Announces Partnership with the Foundation for Prader-Willi (FPWR)
19 Apr 2021 //
GLOBENEWSWIRE
Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting
14 Apr 2021 //
GLOBENEWSWIRE
Feedback from FDA Providing a Regulatory Path Forward for Saniona`s Tesomet
08 Mar 2021 //
GLOBENEWSWIRE
Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet
03 Mar 2021 //
GLOBENEWSWIRE
Saniona’s Ownership Stake in Scandion Oncology Reduced Below 5%
15 Dec 2020 //
GLOBENEWSWIRE
Saniona Reports Positive Topline Results from Tesomet Ph2 Open-Label
23 Nov 2020 //
GLOBENEWSWIRE
Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5
05 Nov 2020 //
GLOBENEWSWIRE
Saniona receives pre-IND feedback from FDA on regulatory path for Tesomet
09 Oct 2020 //
GLOBENEWSWIRE
Saniona Announces Poster Presentation at the European Congress of Endocrinology
24 Aug 2020 //
GLOBENEWSWIRE
Saniona Receives Positive Feedback from FDA on Regulatory Path for Tesomet
08 Jun 2020 //
GLOBENEWSWIRE
Saniona Reports Positive Topline Results from Phase 2 Trial of Tesomet
21 Apr 2020 //
GLOBENEWSWIRE
